Management of Microvascular Changes on MRI

Primary Management Strategy

The American Academy of Neurology recommends aggressive vascular risk factor modification to prevent progression of microvascular disease, with the specific approach determined by the pattern, extent, and clinical context of the findings 1, 2

Assess for acute symptoms: If the patient presents with sudden cognitive changes or stroke symptoms within 1-2 weeks, obtain MRI with diffusion-weighted imaging (DWI) to evaluate for acute ischemia 1
Quantify white matter disease severity: Use validated visual rating scales like the Fazekas scale—beginning confluent or confluent subcortical white matter hyperintensities (WMH) are sufficient to cause cognitive dysfunction 1
Document microbleeds and superficial siderosis: Blood-sensitive T2*-weighted sequences (susceptibility-weighted imaging or gradient echo) should be included to detect chronic hemorrhagic lesions, which have critical implications for antithrombotic therapy decisions 1, 3

Obtain the following tests to identify modifiable risk factors and alternative etiologies: Complete blood count (CBC), Thyroid-stimulating hormone (TSH), Vitamin B12, Calcium, electrolytes, creatinine, Alanine transaminase (ALT), Lipid panel, Hemoglobin A1c (HbA1c) 1, 2, 5

The American Heart Association recommends targeting systolic blood pressure <140 mmHg in most patients 6
Optimize diabetes control (target HbA1c based on individual patient factors) 1
Manage hyperlipidemia according to current guidelines 1
Smoking cessation 1

The presence and number of microbleeds on gradient echo or susceptibility-weighted imaging fundamentally alters antithrombotic management 3, 7
Small number of microbleeds (<5): No statistically significant increase in symptomatic intracranial hemorrhage risk with intravenous thrombolysis; antithrombotic therapy can generally proceed 8, 9
Multiple microbleeds (>5): Risk is underdetermined; exercise extreme caution with antithrombotic therapy 8
Lobar microhemorrhages with CAA pattern: Decision analysis studies recommend against anticoagulation even in the presence of atrial fibrillation 5, 9

Conduct thorough neuropsychological testing focusing on domains affected by microvascular disease: Memory function, Executive function, Attention and processing speed 1, 2
Schedule regular follow-up with repeat cognitive assessment to monitor for progression 2
Consider repeat MRI to track structural changes, particularly if clinical decline occurs 1

FDG-PET/CT brain imaging: Consider if clinical suspicion for neurodegenerative disease is high to differentiate vascular cognitive impairment from other causes 2
Vascular imaging (CTA or MRA): Not routinely indicated for surveillance of established microvascular disease, but useful if considering intervention for large vessel stenosis 10

Establish dialogue about the patient's understanding of cognitive symptoms and MRI findings 2
Explain that the presence of WMH alone does not establish a diagnosis of vascular dementia 2
Emphasize the importance of vascular risk factor control in preventing progression 2
Discuss the threshold of vascular damage required to cause dysfunction varies between patients due to differing cognitive reserve 1